Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
368
resultados
Última actualización
02/11/2026 [10:35:00]
Resultados 150 a 175 de 368
Resumen de: WO2026205616A1
The present invention relates to an anti-APP antibody or an antigen-binding fragment thereof, and uses thereof. Specifically, the anti-APP antibody or antigen-binding fragment thereof according to the present invention may be utilized for analysis and detection of cell membrane APP, and further for diagnosis of APP-related diseases.
Resumen de: WO2026207317A1
A method for screening a subject in need thereof for amyotrophic lateral sclerosis (ALS) or slowing a progression of ALS, wherein the method includes measuring a level of at least a biomarker in the subject, such as without limitation by using a synthetic antibody, determining an ALS status indicator as a function of the measurement, and optionally providing a treatment to slow the progression of ALS as a function of the ALS status indicator, wherein the at least a biomarker includes a trimeric superoxide dismutase 1 (SOD1).
Resumen de: WO2025050066A1
The present disclosure provides compositions for activating TERT expression and methods of using the same for treating or ameliorating aging, aging-related diseases, and neurodegenerative conditions.
Resumen de: US20260298931A1
0000 A method for detecting colorectal cancer DNA using a lateral flow assay includes: extracting a blood sample (S100); loading the blood sample on a lateral flow assay (LFA) kit (S110); amplifying a specific target circulating tumor DNA (ctDNA) fragment using single nucleotide polymorphism (SNP) typing based on a loop-mediated isothermal amplification (LAMP) device on the kit (S130); allowing the amplified SNP sequence to move along a nitrocellulose membrane and binding to a gold nanoparticle probe to form a DNA-AuNP complex (S140); and color-developing a first probe to be visually detected in the complex forming process (S150), so as to detect whether colorectal cancer mutant DNA exists in the blood sample based on the color development.
Resumen de: WO2026206235A1
A mixing device for blending and measuring the thickness of fluids comprises a rotational motor with a motor shaft and a blade with a blade shaft. A torque sensor assembly connects the motor shaft to the blade shaft. The mixing motor operates in two modes. In mixing mode, the motor rotates in one direction at a high speed to mix and thicken fluids. In measuring mode, the motor rotates in the opposite direction at a low speed to assess the fluid's thickness. The rotation speed in this mode adapts to the thickness level of the fluid. A lift mechanism adjusts the height of a fluid container, allowing the blade to reach different depths for thorough mixing. Additionally, the device includes a powder container that dispenses a measured amount of thickening powder at the edge of the fluid container in a single release.
Resumen de: US20260298865A1
0000 A screen-printed sensor for detecting aluminum ions in food and biological samples is provided. The sensor includes an aluminum ion-selective membrane containing quercetin as an aluminum ionophore and multi-walled carbon nanotubes. The sensor provides a low-cost point of analysis method to determine aluminum ion concentration in a range of from 0.008 to 1070 μM in food and beverage materials, reflecting the general detection capability of the sensor under aqueous conditions.
Resumen de: WO2026199081A1
A multiplex biosensing device and system are disclosed, including a plurality of multiplex biosensing electrodes configured for simultaneous, real-time detection of multiple biomolecule markers. The multiplex biosensing electrodes may comprise working electrodes modified with diverse biosensing platforms. The biosensing platforms may include molecularly imprinted polymers, immunocomplex reactions, enzymatic reactions, or DNA hybridization, each customized to detect specific biomarkers. The device further includes a microfluidic delivery mechanism designed for the sequential processing and delivery of biofluid samples and reagents, using a separation or filter media to remove impurities. The multiplex biosensor system integrates the multiplex biosensing device and a detection apparatus may be wirelessly connected via Bluetooth or other communication modules, enabling remote, real-time data monitoring and analysis. The system supports various biofluids, including blood, plasma, urine, saliva, sputum, and sweat, facilitating diverse applications in health diagnostics, environmental monitoring, and food safety.
Resumen de: WO2026206998A1
Disclosed herein are methods and compositions for determining survival and treatment responsiveness of subjects with ovarian cancer. Specifically, the disclosure is directed to prognostic glucocorticoid receptor activity signatures for ovarian cancer. Also provided are methods for predicting responsiveness to certain cancer therapies (e.g., selective glucocorticoid receptor modulators (SGRMs)).
Resumen de: US20260298949A1
0000 Disclosed and claimed are compositions containing a calibrator and a stabilizer, wherein the stabilizer includes Diethylaminoethyl-(“DEAE”) dextran; D-Sorbitol, wherein the D-Sorbitol and DEAE-dextran are in a weight ratio from about 1:1 to about 5:2, a buffer; and a non-ionic surfactant; wherein the stabilizer is essentially free of bovine serum albumin; and wherein the calibrator is stabilized under frozen storage conditions, and remains stable when thawed and kept at temperatures of from about 2° C. to about 10° C. Also disclosed are methods of use of the claimed compositions and kits comprising the claimed compositions.
Resumen de: US20260298917A1
0000 This document relates to methods and materials for detecting the presence or absence of misfolded polypeptides in a sample. For example, a sample (e.g., a biological sample or an environmental sample) can be exposed to nanoparticles (e.g., nanoparticles having a size of no more than 2 μm (e.g., no more than 1 μm) such as silica nanoparticles (siNPs) having a size of no more than 2 μm (e.g., siNPs having a size of no more than 1 μm)) during a seeded amplification assay to accelerate the aggregation of misfolded polypeptides present in the sample into fibrils and/or polypeptide aggregates (e.g., globular polypeptide aggregates). In some cases, methods and materials provided herein can be used to determine if a mammal (e.g., a human) has a proteinopathy based, at least in part, in the presence or absence of misfolded polypeptides in a sample obtained from the mammal.
Resumen de: US20260298946A1
The invention relates to a method for selecting a patient suffering stroke for a reperfusion therapy based on determining the level of retinol binding protein-4 (RBP4) and N-terminal fragment of B-type natriuretic peptide (NT-proBNP) in an isolated sample of said patient. The invention also relates to a method of differentiating ischemic stroke from haemorrhagic stroke and to kits comprising reagents to carry out the methods.
Resumen de: US20260294328A1
0000 Disclosed herein are methods for diagnosing Alzheimer's disease in a subject that involves administering to the subject an imaging agent comprising hyperpolarized pyruvate having a nuclear magnetic resonance (NMR)-detectable nucleus; applying radiation to the brain of the subject, wherein the radiation has a frequency that excites electron spin transitions in the DNP agent at an intensity to polarize the NMR-detectable nucleus; detecting magnetic resonance signals in the brain of the subject from nuclear spin transitions in the NMR-detectable nucleus to produce a spectrum measuring bicarbonate (Bic) and lactate (Lac) metabolites; and calculating a Bic/Lac ratio from the measured metabolites, wherein a reduced Bic/Lac ratio compared to control is an indication that the subject has Alzheimer's disease.
Resumen de: US20260297486A1
0000 Disclosed herein are 3D culture systems and methods for producing epithelial tubular organoids, such as intestinal organoids. Also disclosed is a screening method that involves contacting elongated epithelial tubes produced from the disclosed systems and methods with a candidate agent, culturing the elongated epithelial tube in a growth medium under growth conditions, and evaluating the elongated epithelial tube for a physiological effect.
Resumen de: AU2025239644A1
Provided herein are medical uses of CD11a-enriched T regulatory cells for treating amyotrophic lateral sclerosis (ALS) or ameliorating a symptom of ALS. Such uses may include longitudinal analysis of biomarkers, such as inflammatory cytokines.
Resumen de: US20260297525A1
Disclosed herein are methods of expanding populations of patrolling monocytes in vitro and in vivo for treatment of sickle-cell disease (SCD), reducing pain and vaso-occlusive events in SCD patients, promoting wound healing, reducing tumor metastases, and treating vascular inflammatory conditions in subjects in need thereof.
Resumen de: KR20260143120A
0001a 본원은 LAMP1(Lysosome-Associated Membrane Protein 1) 및 OPTN(Optineurin)을 유효성분으로 포함하는, 신경 퇴행성 질환 진단용 바이오마커 조성물에 관한 것이다.
Resumen de: EP4814494A1
Provided is a method for identifying molecules and compounds involved in the modulation of lipid synthesis and uptake, wherein said molecule or compound blocks or activates SREBP maturation, comprising contacting cells with a molecule or compound to be tested and observing the presence or absence of domains in the endoplasmic reticulum membrane formed by cholesterol esters with cholesterol or, alternately, localizing SREBP proteins within the cell after said contacting, wherein the molecule or compound is identified as an inhibitor of SREBP maturation when ER domains form within the cell or, alternately, SREBP signal is localized more in the endoplasmic reticulum, whereas the molecule or compound is identified as an activator of SREBP maturation when ER domains are absent or, alternately, SREBP signal is localized more in the nucleus or when its target genes are elevated.
Resumen de: KR20260143067A
본 발명은 퇴행성 뇌질환 치료제 스크리닝용 TDP-43 변이체에 관한 것으로, TDP-43의 특정 영역 돌연변이를 통해 병리적 응집체인 아밀로이드 섬유 형성을 안정적으로 유도함으로써 실제 퇴행성 뇌질환의 병리 현상을 정확히 모사하는 질환 모델을 제공할 수 있다. 또한, 1,6-hexanediol에 대한 저항성을 갖는 고체상의 응집체를 형성하여, 액상 응집체의 병리적 고체상 전이를 제어할 수 있는 치료제 후보 물질을 신속하고 효율적으로 선별할 수 있다. 또한, 효모 및 포유동물 세포 시스템을 이용한 다각적 스크리닝을 통해 약물의 효능 및 세포 독성을 동시에 평가할 수 있는 신뢰성 높은 약물 탐색 플랫폼으로 활용할 수 있다.
Resumen de: CN122836330A
0001 本发明公开了一种阿尔茨海默症早筛传感器的制备方法、传感器及早筛方法，可分别制备电极基底与复合前驱液，将前驱液旋涂固化形成光电复合沟道层，经巯基乙酸与活化液表面活化后，孵育固定Aβ42适配体，再通过牛血清白蛋白封闭非特异位点，制得目标传感器。本发明融合光电化学与晶体管传感技术，实现沟道层光敏与生物识别功能一体化，依托光电协同效应放大微弱电势信号，检出限低、检测速度快、能耗低。本发明有效杜绝非特异性干扰，检测特异性与灵敏度优异，制备工艺简单、成本低廉且易于量产，创新了Aβ42检测思路，适配阿尔茨海默症早期低浓度样本筛查，具备极高的临床推广价值。
Resumen de: WO2026200905A1
The present application relates to an antibody specifically targeting α-synuclein and a use of the antibody. The present application also relates to a humanized antibody involved in the antibody and a use of the humanized antibody.
Resumen de: CN122836171A
本发明提供了用于测定外泌体蛋白的试剂在制备用于确定受试者衰老进程、用于在受试者中鉴定无症状期阿尔茨海默病和/或用于在受试者中区分无症状期阿尔茨海默病与正常衰老的试剂盒中的用途，其中，所述外泌体蛋白包括：C1QC、CO9、GP1BB、RSU1、A0A0G2JRQ6和ADA10。本发明基于六种特定外泌体蛋白的表达水平的动态变化速率分析，可精准区分无症状阿尔茨海默病与正常衰老，适用于AD早期筛查、MCI患者分层管理、疾病进展监测及健康体检，具有重要的临床实用价值和应用前景。
Resumen de: CN122832097A
本发明公开了抗神经丝轻链蛋白的单克隆抗体及其应用，属于单克隆抗体技术领域，具体涉及抗神经丝轻链蛋白的单克隆抗体、抗体对及其在检测试剂盒中的应用；该单克隆抗体包括单克隆抗体2H12和单克隆抗体6E7。本发明提供的单克隆抗体具有高度特异性、高结合力和高亲和力，将其应用于制备神经丝轻链蛋白的免疫检测试剂，有助于显著提升免疫检测试剂的热稳定性，增强其抗钩状效应能力，提高对神经丝轻链蛋白的检测灵敏度和精密度，为神经系统疾病的临床诊断提供了可靠的工具。
Resumen de: CN122836331A
本发明涉及生物医药领域，公开了ATP6V0A1 K303琥珀酰化位点的应用，包括ATP6V0A1 K303琥珀酰化位点在制备用于筛选治疗神经退行性疾病的候选药物的试剂盒中的应用、筛选治疗神经退行性疾病的候选药物的体外方法以及用于筛选治疗神经退行性疾病的候选药物的试剂盒，ATP6V0A1蛋白的氨基酸序列如SEQ ID NO:1所示，K303位点为第303位赖氨酸，检测剂包括用于LC‑MS/MS检测修饰肽段NWFVKSuccinylVR的试剂。本发明通过将该位点琥珀酰化修饰水平用于候选药物筛选，使筛选结果与该位点琥珀酰化修饰水平相对应，为筛选使该位点修饰水平升高的候选药物提供技术基础。
Resumen de: CN122832039A
0001 本发明公开了一种靶向补体C5的多肽及其应用和产品，属于多肽制备技术领域。本发明首次提供了一种C5靶向多肽（命名为C548），该多肽可显著抑制炎症状态下膜攻击复合物（MAC）的组装，有效减轻炎症介导的组织损伤，为自身免疫性疾病及其他补体异常相关疾病提供了一种潜在的替代抗体治疗策略。
Nº publicación: CN122836325A 29/09/2026
Solicitante:
希森美康株式会社
Resumen de: US20260298944A1
0000 Provided is a method for measuring a polypeptide aggregate in a sample, wherein the method comprises obtaining information regarding a concentration of the polypeptide aggregate in the sample using a calibrator, and the calibrator comprises a complex comprising: an oligopeptide comprising an epitope of the polypeptide aggregate; a hydrophilic polymer chain not comprising the epitope; and a carrier particle.
BOPI
Sede Electrónica
